Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3311-3312

  Saloustros, Emmanouil ^a   Stratakis, Constantine A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; GONADORELIN AGONIST; GOSERELIN; GYRASE INHIBITOR; MITOXANTRONE; TRIPTORELIN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE FERTILITY; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PREMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FERTILITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOADJUVANT THERAPY; OVARY; TRIPTORELIN PAMOATE;

EID: 84866536161     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.6197     Document Type: Letter

References (8)

1. Munster PN, Moore AP, Ismail-Khan R, et al: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533-538, 2012
2. Partridge AH: Ovarian suppression for prevention of premature menopause and infertility: Empty promise or effective therapy? J Clin Oncol 30:479-481, 2012
3. Gerber B, von Minckwitz G, Stehle H, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011
4. Leonard RC, Adamson D, Anderson R, et al: The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 28:89s, 2010 (suppl 15; abstr 590)
5. Del Mastro L, Boni L, Michelotti A, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA 306:269-276, 2011
6. Badawy A, Elnashar A, El-Ashry M, et al: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril 91:694-697, 2009
7. Flaig TW, Tangen CM, Hussain MH, et al: Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26:1532-1536, 2008
8. Le Deley MC, Suzan F, Cutuli B, et al: Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25:292-300, 2007 (Pubitemid 350003017)